OBJECTIVES: This study investigates the impact of the COVID-19 pandemic on breast cancer (BC) care, analyzing treatment delays and factors associated with them.

METHODS: This retrospective cross-sectional study analyzed data from the Oncology Dynamics (OD) database. Surveys of 26,933 women with BC performed between January 2021 and December 2022 in Germany, France, Italy, the United Kingdom, and Spain were examined. The study focused on determining the prevalence of treatment delays due to the COVID-19 pandemic, considering factors such as country, age group, treating facility, hormone receptor status, tumor stage, site of metastases, and ECOG (Eastern Cooperative Oncology Group) status. Baseline and clinical characteristics were compared for patients with and without therapy delay using chi-squared tests, and a multivariable logistic regression analysis was conducted to explore the association between demographic and clinical variables and therapy delay.

RESULTS: The present study found that most therapy delays lasted less than 3 months (2.4%). Factors associated with higher risk of delay included being bedridden (OR: 3.62; 95% CI: 2.51–5.21), receiving neoadjuvant therapy (OR: 1.79; 95% CI: 1.43–2.24) compared to adjuvant therapy, being treated in Italy (OR: 1.58; 95% CI: 1.17–2.15) compared to Germany or treatment in general hospitals and non-academic cancer facilities (OR: 1.66, 95% CI: 1.13–2.44 and OR: 1.54; 95% CI: 1.14–2.09, respectively) compared to treatment by office-based physicians.

CONCLUSIONS: Addressing factors associated with therapy delays, such as patient performance status, treatment settings, and geographic location, can help guide strategies for improved BC care delivery in the future.